Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
125M
-
Number of holders
-
308
-
Total 13F shares, excl. options
-
105M
-
Shares change
-
-4.8M
-
Total reported value, excl. options
-
$9.6B
-
Value change
-
-$396M
-
Put/Call ratio
-
0.74
-
Number of buys
-
162
-
Number of sells
-
-148
-
Price
-
$91.10
Significant Holders of Apellis Pharmaceuticals, Inc. - Common Stock (APLS) as of Q2 2023
388 filings reported holding APLS - Apellis Pharmaceuticals, Inc. - Common Stock as of Q2 2023.
Apellis Pharmaceuticals, Inc. - Common Stock (APLS) has 308 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 105M shares
of 125M outstanding shares and own 84.21% of the company stock.
Largest 10 shareholders include Avoro Capital Advisors LLC (11.1M shares), VANGUARD GROUP INC (9.4M shares), PRICE T ROWE ASSOCIATES INC /MD/ (7.07M shares), WELLINGTON MANAGEMENT GROUP LLP (6.66M shares), BlackRock Inc. (5.75M shares), T. Rowe Price Investment Management, Inc. (5.64M shares), EcoR1 Capital, LLC (5.45M shares), FMR LLC (4.23M shares), Octagon Capital Advisors LP (2.62M shares), and STATE STREET CORP (2.28M shares).
This table shows the top 308 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.